More Alberta seniors are now eligible for a provincially funded RSV vaccine.The provincial government announced in October it ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In the first domestic ITF Masters event of 2025 on Canadian soil, the hosts dominated by claiming every trophy at the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

Pfizer Inc. (NYSE:PFE – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders bought 294,496 call options on the stock. This represents an increase of ...

Study findings underscore the effectiveness of a dual approach to RSV prevention. The RSVpreF vaccine induces passive immunity by transferring protective antibodies to the fetus, while nirsevimab, a ...

The rollout of 2 major interventions to prevent severe respiratory syncytial virus (RSV) in infants—the RSV prefusion F (RSVpreF; ABRYSVO) vaccine for pregnant individuals and the monoclonal ...

By May 2024, the FDA approved three RSV vaccines for adults. The three FDA-approved RSV vaccines for adults 60 and older are GSK’s AREXVY, Pfizer’s ABRYSVO and Moderna’s mRESVIA. Initially, in June ...